fluorodopa f 18 has been researched along with Digestive System Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aide, N; de Beco, V; Grahek, D; Grangé, JD; Gutman, F; Kerrou, K; Lotz, JP; Montravers, F; Ruszniewski, P; Talbot, JN | 1 |
| Al-Nahhas, A; Ambrosini, V; Campana, D; Castellucci, P; Fanti, S; Farsad, M; Franchi, R; Montini, G; Nanni, C; Rubello, D; Tomassetti, P | 1 |
1 trial(s) available for fluorodopa f 18 and Digestive System Neoplasms
| Article | Year |
|---|---|
Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.
Topics: Adult; Aged; Aged, 80 and over; Biopsy, Needle; Digestive System Neoplasms; Dihydroxyphenylalanine; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Positron-Emission Tomography; Radionuclide Imaging; Radiopharmaceuticals; Sensitivity and Specificity; Somatostatin; Tomography, X-Ray Computed; Ultrasonography | 2007 |
1 other study(ies) available for fluorodopa f 18 and Digestive System Neoplasms
| Article | Year |
|---|---|
Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?
Topics: Adult; Aged; Carcinoid Tumor; Digestive System Neoplasms; Dihydroxyphenylalanine; Endocrine Gland Neoplasms; Female; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Somatostatin; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Somatostatin | 2006 |